Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers November 19, 2017
Pharmacy Choice - Pharmaceutical News - Matinas BioPharma Retains JSB Partners to Pursue Strategic Options for MAT9001 [Sport360] - November 19, 2017

Pharmacy News Article

 9/13/17 - Matinas BioPharma Retains JSB Partners to Pursue Strategic Options for MAT9001 [Sport360]

(GlobeNewswire) - Matinas BioPharma Holdings, Inc. (Matinas BioPharma or the Company) (NYSE MKT:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, today announced that it has retained JSB Partners, a global life sciences advisor, to identify a partner for the Companys legacy cardiovascular product candidate, MAT9001.

MAT9001 is a uniquely engineered, prescription-only omega-3 fatty acid medication comprising DPA and is specifically designed to provide a differentiated pharmacotherapy for the treatment of dyslipidemia.

We believe that MAT9001, and its proprietary gel cap delivery system, has the potential to be a best-in-class product for the treatment of dyslipidemia. Although we continue to focus our development efforts and resources on our disruptive cochleate delivery platform technology given the vast opportunity presented by our MAT2203 and MAT2501 infectious disease products, we believe that it is the ideal time to formalize our efforts to realize the potentially significant value that MAT9001 possesses, particularly in light of the forthcoming data from Amarins REDUCE-IT outcomes trial due in 2018, remarked Jerome D. Jabbour, President and co-Founder of Matinas BioPharma. We are thrilled to be working with JSB Partners as we evaluate the strategic opportunities available for MAT9001. JSB Partners experience and track record speaks for itself and we believe they are well positioned to assist us in maximizing MAT9001s value on a domestic and international basis.

In Matinas BioPharmas head-to-head comparative pharmacokinetic and pharmacodynamic study versus Amarins Vascepa (icosapent ethyl), MAT9001 met all of its primary and secondary endpoints and demonstrated statistically significant superiority over Vascepa for omega-3 bioavailability (baseline adjusted AUC and Cmax, approximately 6-fold higher with MAT9001 on day 14, with very high statistical significance) and triglyceride reduction (median TG-reduction from baseline: -33.2% for MAT9001 versus -10.5% for Vascepa; p500 mg/dL) as the lead indication. Promising pre-clinical studies with DPA and MAT9001 indicate distinctive therapeutic response properties. The Company believes that its development program and related clinical investigations may yield an improved therapeutic profile compared to existing therapies, based on MAT9001`s differentiating mechanistic features associated with its unique composition.

About Matinas BioPharmaMatinas BioPharma is a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications. The Company`s proprietary, disruptive technology utilizes lipid-crystal nano-particle cochleates to nano-encapsulate existing drugs, making them safer, more tolerable, less toxic and orally bioavailable.

The Company`s lead anti-infective product candidates, MAT2203 and MAT2501, position Matinas BioPharma to become a leader in the safe and effective delivery of anti-infective therapies utilizing its proprietary lipid-crystal nano-particle cochleate formulation technology. For more information, please visit www.matinasbiopharma.com and connect with the Company on Twitter, LinkedIn, Facebook, and Google+.

Forward Looking Statements: This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company`s strategic focus and the future development of its product candidates and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements. Forward-looking statements include words such as expects, anticipates, intends, plans, could, believes, estimates and similar expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, the Companys ability to identify and pursue business development or partnership opportunities for its products on favorable terms, if at all, our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials of our product candidates; our ability to successfully complete research and further development and commercialization of our product candidates; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to protect the Company`s intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company`s products; and the other factors listed under Risk Factors in our filings with the SEC, including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this release. Except as may be required by law, the Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Matinas BioPharmas product candidates are all in a development stage and are not available for sale or use.

Investor and Media ContactJenene ThomasInvestor Relations and Corporate Communications AdvisorJenene Thomas Communications, LLCPhone: +1 (908) 938-1475Email: jenene@jenenethomascommunications.com



(c) 2017 Gulf Sports Media All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info).

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Nov 20: Obesity Management: Overview of Pharmacotherapy
Nov 21: Standards of Practice for Filling Controlled Substance Prescriptions in Florida
Nov 22: Medical Marijuana: Examining the Science, Not the Politics
Nov 27: Drug Diversion and the Law: Updates and Considerations
Nov 28: An Integrative Approach to Managing Arthritis
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415